Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
VolitionRx Limited (NYSE AMERICAN: VNRX) has appointed SAGE Healthcare Private Limited as a non-exclusive licensee and distributor for its Nu.Q® Vet Cancer Screening Test in Singapore. The test launch is slated for Q1 2022, with plans for further expansion across Asia. Volition aims to establish similar agreements globally to enhance accessibility to the Nu.Q® Test. Ongoing negotiations with multinational veterinary companies are progressing, with potential contracts expected soon.
VolitionRx Limited (VNRX) reported its third quarter financial results for 2021, highlighting a cash position of $22.9 million and an average monthly cash burn rate of $1.7 million. The company is in advanced negotiations with three major veterinary firms for licensing agreements and has expanded its intellectual property assets. Despite a net loss of $7.2 million this quarter, increased from $5.6 million in the prior quarter, Volition is optimistic about its Nu.Q® products' potential and upcoming launches. A conference call is scheduled for November 11, 2021.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced a conference call on November 11, 2021, at 8:00 a.m. Eastern time to discuss its third quarter 2021 financial results and provide a business update. The call will include updates on ongoing clinical trials and key events from Q3 2021. CEO Cameron Reynolds, along with other executives, will lead the discussion. Investors can access a live audio webcast from their investor relations page. A telephone replay will be available until November 25, 2021.
VolitionRx Limited (NYSE AMERICAN: VNRX) presented two significant abstracts at the 2021 Veterinary Cancer Society Conference. The first highlights the effectiveness of Nu.Q® in monitoring disease response and progression in cancer-bearing dogs, showing potential for early identification of remission. The second abstract introduces Nu.Q® Capture, an enrichment tool for analyzing circulating nucleosomes in dogs with lymphoma. These advancements pave the way for a second Nu.Q® Vet product launch planned for 2022, reinforcing Volition's commitment to improving cancer diagnostics in veterinary medicine.
VolitionRx Limited (NYSE AMERICAN: VNRX) reported strong progress in its second quarter ended June 30, 2021, highlighting a solid balance sheet with $27.9 million in cash. The company has expanded its intellectual property portfolio, added key personnel, and published significant clinical research. Notably, the beta launch of the Nu.Q® Vet platform received high interest for licensing. However, they reported a net loss of $5.6 million for the quarter and continue to face operational challenges due to the pandemic.
VolitionRx Limited (NYSE AMERICAN: VNRX) will host a conference call on August 12, 2021, at 8:00 a.m. Eastern time to discuss its second quarter 2021 financial results and provide a business update. The call will feature insights from key executives, including Cameron Reynolds, CEO, and Terig Hughes, CFO. Topics will include new and ongoing clinical trials and significant events from the second quarter. Interested parties can join via dial-in or access a live audio webcast on the company's investor relations page.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced promising results from its Nu.Q® NETs assay in COVID-19 studies presented at the ISTH Congress 2021. This assay correlates with disease severity, predicting future COVID-19 outcomes and assisting in risk stratification for treatment. The findings suggest potential in monitoring disease progression, particularly in intensive care scenarios. Ongoing large studies on COVID-19, sepsis, and more are expected to yield further data shortly, indicating a strong pipeline for Volition's diagnostic capabilities.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced its first-quarter financial results for 2021, reporting approximately $33.1 million in cash, significantly up from $19.4 million at the end of 2020. The company added approximately $20.3 million through stock offerings and secured $4 million in non-dilutive funding. Leadership was strengthened with new executive appointments. The company expanded its intellectual property with 28 patent families and published three clinical papers, demonstrating progress in its Nu.Q® diagnostic platform, particularly in veterinary applications.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced a conference call scheduled for May 12, 2021, at 8:00 a.m. Eastern time to report its first quarter 2021 financial results. The call will be hosted by CEO Cameron Reynolds and CFO Terig Hughes, discussing new clinical trials and significant milestones. The call will also be available via a live audio webcast on Volition's investor relations website, with a replay option available until May 26, 2021.
VolitionRx Limited (NYSE AMERICAN: VNRX) announced the publication of a significant paper in Scientific Reports about its Nu.Q® Capture technology. This paper details a novel method for detecting histone modifications in cancer patients' blood, potentially leading to new biomarkers for colorectal cancer. CEO Cameron Reynolds highlighted the publication as a crucial advancement in liquid biopsy diagnostics. The study revealed that Nu.Q® Capture allows precise analysis of nucleosomes with minimal plasma, underscoring its potential in biomarker discovery and cancer diagnosis.